Dr. Jeffrey Scott Charpentier, M.D. Psychiatry & Neurology - Neurology Medicare: Accepting Medicare Assignments Practice Location: 81 Prominence Ct Ste 200, Dawsonville, GA 30534 Phone: 770-219-6520 |
News Archive
It seems like a no-brainer, and it is: Take the junk food out of school vending machines and cafeterias, and kids will eat less junk food, according to a new study that took place in Connecticut.
The study of tobacco has been the life-long focus of his research and now, Peter Shields, MD, deputy director of the Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, has led the effort to edit a special-edition of Cancer Epidemiology, Biomarkers & Prevention (CEBP) dedicated to best research practices in tobacco science from researchers the world over.
Updated guidelines for physicians that represent best practices for using magnetic resonance imaging (MRI) to newly diagnose breast cancer and to make treatment decisions for breast cancer were published today in the Journal of the National Comprehensive Cancer Network.
Watson Pharmaceuticals, Inc. and Natco Pharma Limited today confirmed an exclusive, U.S. development and license agreement, to develop and commercialize lenalidomide 5, 10, 15 and 25 mg tablets. The companies also confirmed that Natco has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market its lenalidomide 5, 10, 15 and 25 mg product. Natco's lenalidomide tablets are generic versions of Celgene's Revlimid ® Tablets.
Researchers have developed a new MRI contrast dye that enables more accurate and safer detection of early-stage liver disease than currently approved agents.
› Verified 1 days ago